LLY · News · 20260826N

Medicare GLP-1 Bridge Program

ELI LILLY & Co · 2026-08-26 · Importance 17 · Surprise 24

A real-world study of adults older than 55 with overweight or obesity found that sustained treatment with Zepbound (tirzepatide) was associated with lower healthcare costs than treatment in similar untreated adults. The savings were driven partly by fewer hospital admissions and emergency-department visits. The study indicated that meaningful cost savings emerged as early as 12 months, supporting the potential value proposition of Lilly’s Medicare GLP-1 Bridge program.

Key facts

• For adults over the age of 55, including patients in Medicare's GLP-1 Bridge program, the study reported that lower costs translate into meaningful savings as early as 12 months into treatment. source
• Eli Lilly announced a real-world study showing that staying on Zepbound (tirzepatide) for weight management lowered healthcare costs over time relative to similar untreated adults for adults over 55 with overweight or obesity. source
• The study found that individuals treated with Zepbound had lower rates of hospital admissions and emergency department visits. source